Subscribe to RSS
DOI: 10.1055/s-0038-1650220
β2-Glycoprotein I Modulates the Anticoagulant Activity of Activated Protein C on the Phospholipid Surface
Publication History
Received 28 April 1995
Accepted after resubmission 19 September 1995
Publication Date:
10 July 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/199601/lookinside/thumbnails/10-1055-s-0038-1650220-1.jpg)
Summary
The objective of this study was to determine whether (β2-glycoprotein I (β2GPI) has procoagulant activity by inhibiting the anticoagulant activity of activated protein C (APC). β2GPI inhibited significantly the APC-catalyzed inactivation of factor Va in an assay using factor V-deficient plasma and physiological levels of protein S and factor Va. This inhibitory effect was diminished by the addition of increasing concentrations of phospholipids, suggesting that β2GPI competitively inhibits the binding of APC to the phospholipid surface. β2GPI inhibited weakly factor Va- and phospholipid-dependent prothrombinase activity at concentrations similar to those to inhibit APC activity. The depletion of β2GPI from plasma led to only a slight shortening of the diluted Russell’s viper venom-dependent clotting time, but to a strong and significant potentiation of the anticoagulant activity of APC. These results suggest that under certain physiological conditions β2GPI has procoagulant property by inhibiting the phospholipid-dependent APC anticoagulant activity.
-
References
- 1 Polz E, Kostner GM. The binding of β2-glycoprotein-I to human serum lipoproteins - distribution among density fractions. FEBS Lett 1979; 102: 183-186
- 2 Wurm H. β2-Glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles. Int J Biochem 1984; 16: 511-515
- 3 Schousboe I. β2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 1086-1091
- 4 Nimpf J, Wurm H, Kostner GM. Interaction of β2-glycoprotein-I with human blood platelets: influence upon the ADP-induced aggregation. Thromb Haemost 1985; 54: 397-401
- 5 Nimpf J, Bevers EM, Bomans PHH, Till U, Wurm H, Kostner GM, Zwaal RFA. Prothrombinase activity of human platelets is inhibited by β2-glyco-protein-I. Biochim Biophys Acta 1986; 884: 142-149
- 6 Bancsi LFJMM, van der Linden IK, Bertina RM. β2-Glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost 1992; 67: 649-653
- 7 Triplett DA. Antiphospholipid antibodies and thrombosis - a consequence, coincidence, or cause?. Arch Pathol Lab Med 1993; 117: 78-88
- 8 Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other “antiphospholipid” autoantibodies. Blood 1994; 84: 2854-2867
- 9 Viard J-P, Amoura Z, Bach J-F. Association of anti-β2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992; 93: 181-186
- 10 Martinuzzo ME, Forastiero RR, Carreras LO. Anti-β2 glycoprotein I antibodies: detection and association with thrombosis. Br J Haematol 1995; 89: 397-402
- 11 Galli M, Comfurius P, Barbui T, Zwaal RFA, Bevers EM. Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anti-cardiolipin antibodies. Thromb Haemost 1992; 68: 297-300
- 12 Suzuki K. Protein C. In: Molecular basis of thrombosis and hemostasis High KA, Roberts HR. eds Marcel Dekker, Inc; New York: 1995. pp 393-424
- 13 Suzuki K. Protein S. In: Molecular basis of thrombosis and hemostasis High KA, Roberts HR. eds Marcel Dekker, Inc; New York: 1995. pp 459-478
- 14 Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell 1993; 72: 477-480
- 15 Keeling DM, Wilson AJG, Mackie IJ, Isenberg DA, Machin SJ. Role of β2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitro. J Clin Pathol 1993; 46: 908-911
- 16 Walker FJ. Does beta-2-glycoprotein I inhibit the interaction between protein S and C4b-binding protein?. Thromb Haemost 1993; (abstr) 69: 930
- 17 Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-462
- 18 Miletich JP, Broze GJ, Majerus PW. The synthesis of sulfated dextran beads for isolation of human plasma coagulation factors II, IX, and X. Anal Biochem 1980; 105: 304-310
- 19 Suzuki K, Stenflo J, Dahlbäck B, Teodorsson B. Inactivation of human coagulation factor V by activated protein C. J Biol Chem 1983; 258: 1914-1920
- 20 Dahlbäck B. Purification of human vitamin K-dependent protein S and its limited proteolysis by thrombin. Biochem J 1983; 209: 837-846
- 21 Dahlbäck B. Purification of human C4b-binding protein and formation of its complex with vitamin K-dependent protein S. Biochem J 1983; 209: 847-856
- 22 Suzuki K, Dahlbäck B, Stenflo J. Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem 1982; 257: 6556-6564
- 23 DiScipio RG, Hermodson MA, Davie EW. Activation of human factor X (Stuart factor) by a protease from Russell’s viper venom. Biochemistry 1977; 16: 5253-5260
- 24 lino M, Takeya H, Nishioka J, Nakagaki T, Tamura K, Suzuki K. The role of human factor X activation peptide in activation of factor X by factor IXa. J Biochem 1994; 116: 335-340
- 25 Suzuki K, Nishioka J, Hashimoto S. Regulation of activated protein C by thrombin-modified protein S. J Biochem 1983; 94: 699-705
- 26 DiScipio RG, Hermodson MA, Yates SG, Davie EW. A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S. Biochemistry 1977; 16: 698-706
- 27 Dahlbäck B. Human coagulation factor V purification and thrombin-catalyzed activation. J Clin Invest 1980; 66: 583-591
- 28 De Frutos PG, Alim RIM, Hardig Y, Zoller B, Dahlbäck B. Differential regulation of α and β chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S. Blood 1994; 84: 815-822
- 29 Suzuki K, Nishioka J. Binding site for vitamin K-dependent protein S on complement C4b-binding protein. J Biol Chem 1988; 263: 17034-17039
- 30 Hayashi T, Nishioka J, Shigekiyo T, Saito S, Suzuki K. Protein S-Toku-shima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S. Blood 1994; 83: 683-690
- 31 Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994; 269: 816-819
- 32 Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell’s viper venom time for the diagnosis of lupus anticoagulants. Blood 1986; 68: 869-874
- 33 Nelson RM, Long GL. Solution-phase equilibrium binding interaction of human protein S with C4b-binding protein. Biochemistry 1991; 30: 2384-2390
- 34 Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 1993; 268: 2872-2877
- 35 Heeb MJ, Rosing J, Bakker HM, Fernandez JA, Tans G, Griffin JH. Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci USA 1994; 91: 2728-2732
- 36 Hayashi T, Nishioka J, Suzuki K. Molecular mechanism of the dysfunction of protein STokushima (Lys155→Glu) for the regulation of the blood coagulation system. Biochim Biophys Acta 1995 (in press)
- 37 Oosting JD, Derksen RHWM, Entjes HTI, Bouma BN, de Groot PG. Lupus anticoagulant activity is frequently dependent on the presence of β2-glycoprotein I. Thromb Haemost 1992; 67: 499-502
- 38 Roubey RAS, Pratt CW, Buyon JP, Winfield JB. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon β2-glycoprotein I. J Clin Invest 1992; 90: 1100-1104
- 39 Shi W, Chong BH, Hogg PJ, Chesterman CN. Anticardiolipin antibodies block the inhibition by β2-glycoprotein I of the factor Xa generating activity of platelets. Thromb Haemost 1993; 70: 342-345
- 40 Nomura S, Fukuhara S, Komiyama Y, Takahashi H, Matsuura E, Nakagaki T, Funatsu A, Sugo T, Matsuda M, Koike T. β2-Glycoprotein I and anticardiolipin antibody influence factor Xa generation but not factor Xa binding to platelet-derived microparticles. Thromb Haemost 1994; 71: 526-530
- 41 Oosting JD, Derksen RHWM, Hackeng TM, van Vliet M, Preissner KT, Bouma BN, de Groot PG. In vitro studies of antiphospholipid antibodies and its cofactor, β2-glycoprotein I, show negligible effects on endothelial cell mediated protein C activation. Thromb Haemost 1991; 66: 666-671
- 42 Roubey RAS, Pratt CW, Winfield JB. β2-Glycoprotein-I-dependent lupus anticoagulant activity is inhibited by hexagonal (II) phase phospholipid. Arthritis Rheum 1992; 35 (abstr): S 69
- 43 Kostetskii E, Gerasimenko NI, Kushnerova NF. The phospholipid composition of organs and tissues of rabbit. Biokhimiia 1977; 42: 671-676
- 44 Hagihara Y, Goto Y, Kato H, Yoshimura T. Role of the N- and C-terminal domains of bovine β2-glycoprotein I in its interaction with cardiolipin. J Biochem 1995; 118: 129-136
- 45 Dahlbäck B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995; 85: 607-614
- 46 Bokarewa MI, Blombäck M, Rosen NES. A new variant of interaction between phospholipid antibodies and the protein C system. Blood Coag Fibrinol 1994; 5: 37-41